These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23258912)

  • 1. Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy.
    Abcouwer SF
    Diabetes; 2013 Jan; 62(1):36-8. PubMed ID: 23258912
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models.
    Chen Y; Hu Y; Lin M; Jenkins AJ; Keech AC; Mott R; Lyons TJ; Ma JX
    Diabetes; 2013 Jan; 62(1):261-72. PubMed ID: 23043158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review.
    Sharma N; Ooi JL; Ong J; Newman D
    Aust Fam Physician; 2015 Jun; 44(6):367-70. PubMed ID: 26209985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy.
    Deng G; Moran EP; Cheng R; Matlock G; Zhou K; Moran D; Chen D; Yu Q; Ma JX
    Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5030-5042. PubMed ID: 28979999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate for Diabetic Retinopathy.
    Stewart S; Lois N
    Asia Pac J Ophthalmol (Phila); 2018; 7(6):422-426. PubMed ID: 30058790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy.
    Varghese Z; Moorhead JF; Ruan XZ
    Kidney Int; 2006 May; 69(9):1490-1. PubMed ID: 16672917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy.
    Treacy MP; Hurst TP
    BMC Ophthalmol; 2012 Sep; 12():46. PubMed ID: 22937835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate - a potential systemic treatment for diabetic retinopathy?
    Wong TY; Simó R; Mitchell P
    Am J Ophthalmol; 2012 Jul; 154(1):6-12. PubMed ID: 22709833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
    Rasouli N; Kern PA; Elbein SC; Sharma NK; Das SK
    Pharmacogenet Genomics; 2012 Jul; 22(7):484-97. PubMed ID: 22437669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice.
    Blednov YA; Black M; Benavidez JM; Stamatakis EE; Harris RA
    Alcohol Clin Exp Res; 2016 Mar; 40(3):553-62. PubMed ID: 26857685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
    Keech AC; Mitchell P; Summanen PA; O'Day J; Davis TM; Moffitt MS; Taskinen MR; Simes RJ; Tse D; Williamson E; Merrifield A; Laatikainen LT; d'Emden MC; Crimet DC; O'Connell RL; Colman PG;
    Lancet; 2007 Nov; 370(9600):1687-97. PubMed ID: 17988728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salutary effect of fenofibrate on type 1 diabetic retinopathy via inhibiting oxidative stress-mediated Wnt/β-catenin pathway activation.
    Liu Q; Zhang X; Cheng R; Ma JX; Yi J; Li J
    Cell Tissue Res; 2019 May; 376(2):165-177. PubMed ID: 30610453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of PPARα in retinopathy of type 1 diabetes.
    Pearsall EA; Cheng R; Matsuzaki S; Zhou K; Ding L; Ahn B; Kinter M; Humphries KM; Quiambao AB; Farjo RA; Ma JX
    PLoS One; 2019; 14(2):e0208399. PubMed ID: 30716067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.
    Panigrahy D; Kaipainen A; Huang S; Butterfield CE; Barnés CM; Fannon M; Laforme AM; Chaponis DM; Folkman J; Kieran MW
    Proc Natl Acad Sci U S A; 2008 Jan; 105(3):985-90. PubMed ID: 18199835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients.
    Ju HB; Zhang FX; Wang S; Song J; Cui T; Li LF; Zhang HY
    Medicine (Baltimore); 2017 Aug; 96(31):e7671. PubMed ID: 28767589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Diabetic Retinopathy Outcomes: FIELD Fenofibrate.
    Kalra S; Sahay R
    J Assoc Physicians India; 2018 Dec; 66(12):55-57. PubMed ID: 31313550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenofibrate and Diabetic Retinopathy.
    Knickelbein JE; Abbott AB; Chew EY
    Curr Diab Rep; 2016 Oct; 16(10):90. PubMed ID: 27525681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?
    Balakumar P; Kadian S; Mahadevan N
    Pharmacol Res; 2012 Apr; 65(4):430-6. PubMed ID: 22285932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study.
    Shi R; Zhao L; Qi Y
    BMC Ophthalmol; 2018 Apr; 18(1):100. PubMed ID: 29669526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Fenofibrate and Diabetic Retinopathy in Type 2 Diabetic Patients: A Population-Based Retrospective Cohort Study in Taiwan.
    Lin YC; Chen YC; Horng JT; Chen JM
    Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32751875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.